{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:09:39Z","timestamp":1790640579038,"version":"4.1.0"},"reference-count":29,"publisher":"Informa UK Limited","issue":"17","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2024,5,27]]},"DOI":"10.2217\/fon-2023-0995","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T04:50:09Z","timestamp":1709095809000},"page":"1175-1189","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J","family":"Costa","sequence":"first","affiliation":[{"name":"The University of Alabama at Birmingham, School of Medicine - Medicine - Hematology\u00a0& Oncology, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-7895","authenticated-orcid":false,"given":"Thomas W","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapy, Duke University School of Medicine, Durham, NC 27705-3976, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7839-4917","authenticated-orcid":false,"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[{"name":"Bethanien Hospital, Center for Hematology and Oncology, Frankfurt, 60389, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0808-2237","authenticated-orcid":false,"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus University, 3062, PA Rotterdam, The\u00a0Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5829-9867","authenticated-orcid":false,"given":"Ryan P","family":"Kyle","sequence":"additional","affiliation":[{"name":"Statlog, Montr\u00e9al, Qu\u00e9bec, H3B 2E3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2445-8660","authenticated-orcid":false,"given":"Liliya","family":"Sinyavskaya","sequence":"additional","affiliation":[{"name":"Statlog, Montr\u00e9al, Qu\u00e9bec, H3B 2E3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4752-3218","authenticated-orcid":false,"given":"Patrick","family":"Hlavacek","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY\u00a010001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9555-9899","authenticated-orcid":false,"given":"Aster","family":"Meche","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY\u00a010001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4616-476X","authenticated-orcid":false,"given":"Jinma","family":"Ren","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3332-0180","authenticated-orcid":false,"given":"Alex","family":"Schepart","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY\u00a010001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem","family":"Aydin","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY\u00a010001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Nador","sequence":"additional","affiliation":[{"name":"Pfizer\u00a0Inc, Tadworth, Surrey, KT20 7NS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8333-4676","authenticated-orcid":false,"given":"Marco daCosta","family":"DiBonaventura","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY\u00a010001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.11.007"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2410-2"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7561"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18185"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1800451"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00507-2"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.11.001"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01471-3"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2277850"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2140284"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"issue":"3","key":"e_1_3_8_17_1","first-page":"1","article-title":"Multivariate imputation by chained equations in R","volume":"45","author":"van Buuren S","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. Multivariate imputation by chained equations in R. J. Stat. Softw. 45(3), 1\u201367 (2011).","journal-title":"J. Stat. Softw."},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280206074463"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8206"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2005.00377.x"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.219295"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.178434"},{"key":"e_1_3_8_25_1","volume-title":"Prescribing information.","author":"Xpovio (selinexor)","year":"2019","unstructured":"Xpovio (selinexor). Prescribing information. Karyopharm Therapeutics Inc. Newton, MA, USA (2019)."},{"key":"e_1_3_8_26_1","volume-title":"Summary of product characteristics.","author":"Blenrep (belantamab mafodotin-blmf)","year":"2020","unstructured":"Blenrep (belantamab mafodotin-blmf). Summary of product characteristics. GlaxoSmithKline. Middlesex, UK (2020)."},{"key":"e_1_3_8_27_1","volume-title":"Prescribing information.","author":"Abecma (idecabtagene vicleucel)","year":"2021","unstructured":"Abecma (idecabtagene vicleucel). Prescribing information. Celgene Corporation, Summit, NJ, USA (2021)."},{"key":"e_1_3_8_28_1","volume-title":"Prescribing information.","author":"Carvykti (ciltacabtagene autoleucel)","year":"2022","unstructured":"Carvykti (ciltacabtagene autoleucel). Prescribing information. Janssen Biotech, Inc., Horsham, PA, USA (2022)."},{"key":"e_1_3_8_29_1","volume-title":"Prescribing information.","author":"Tecvayli (teclistamab-cqyv)","year":"2022","unstructured":"Tecvayli (teclistamab-cqyv). Prescribing information. Janssen Biotech, Inc., Horsham, PA, USA (2022)."},{"key":"e_1_3_8_30_1","volume-title":"Prescribing information.","author":"Talvey (talquetamab-tgvs)","year":"2023","unstructured":"Talvey (talquetamab-tgvs). Prescribing information. Janssen Biotech, Inc., Horsham, PA, USA (2023)."},{"key":"e_1_3_8_31_1","volume-title":"Prescribing information.","author":"Elrexfio (elranatamab-bcmm)","year":"2023","unstructured":"Elrexfio (elranatamab-bcmm). Prescribing information. Pfizer, Inc., New York, NY, USA (2023)."}],"updated-by":[{"DOI":"10.1080\/14796694.2024.2413743","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000}}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T05:51:33Z","timestamp":1728453093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":29,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,5,27]]}},"alternative-id":["10.2217\/fon-2023-0995"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0995","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}